Stock Movers Novo Nordisk's Discount, Pernod Ricard Dips, Next Jitters
Nov 26, 2025
A recent Medicare deal guarantees a whopping 71% discount on Novo Nordisk's Ozempic and Wegovy, stirring reactions among investors. Meanwhile, Pernod Ricard faces headwinds as JPMorgan cautions about European consumer staples with rising unemployment on the horizon. Concerns loom over the UK's upcoming budget as retailers, including Next, brace for potential levies. The impact of a minimum wage hike also raises eyebrows, with economists worrying about its effects on productivity and retail performance.
AI Snips
Chapters
Transcript
Episode notes
Medicare Strikes Big Discount On Ozempic
- The US negotiated a 71% discount on Novo Nordisk's Ozempic and Wegovy for Medicare, pricing them at $274/month.
- Analysts say the cuts are largely priced in and likely won't materially harm Novo Nordisk's shares.
Staples Face 2026 Headwinds In Europe
- JPMorgan turned cautious on European consumer staples ahead of 2026 due to expected higher unemployment and weak consumer confidence.
- They favor tobacco and beer over higher-priced spirits like Pernod Ricard, which faces weak demand and a cut outlook.
Minimum Wage Hits Retailers Before Budget
- UK retailers like Next are jittery ahead of the budget amid pre-budget uncertainty and a recent minimum wage hike.
- The wage rise hits firms with large young workforces, raising costs and pressuring shares of retailers and pubs.